3-[5-(4,6-dihydroxy-5'-isopropyl-2'-methoxybiphenyl-3-yl)tetrazol-1-yl]pyrrolidine-1-carboxylic acid tert-butyl ester | 1143624-92-3

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 3-[5-(4,6-dihydroxy-5'-isopropyl-2'-methoxybiphenyl-3-yl)tetrazol-1-yl]pyrrolidine-1-carboxylic acid tert-butyl ester
• 英文别名: Tert-butyl 3-[5-[2,4-dihydroxy-5-(2-methoxy-5-propan-2-ylphenyl)phenyl]tetrazol-1-yl]pyrrolidine-1-carboxylate
• CAS: 1143624-92-3
• 化学式: C₂₆H₃₃N₅O₅
• 分子量: 495.579
• InChiKey: RHOSBLGUDOOAMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  123
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Substituted Tetrazole Compounds and Uses Thereof
  申请人：Yang Rui-Yang

  公开号：US20090130117A1

  公开（公告）日：2009-05-21

  The present invention provides tetrazole compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the tetrazole compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention.

  本发明提供了四唑类化合物及其制备方法。本发明还涉及包含四唑类化合物的药物组合物。本发明提供了通过向需要治疗的受体内给予本发明化合物的治疗有效量来治疗细胞增殖性疾病，如癌症的方法。
• SUBSTITUTED TETRAZOLE COMPOUNDS AND USES THEREOF
  申请人：ArQule, Inc.

  公开号：EP2217580B1

  公开（公告）日：2011-12-21
• US7932279B2
  申请人：——

  公开号：US7932279B2

  公开（公告）日：2011-04-26
• [EN] SUBSTITUTED TETRAZOLE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE TÉTRAZOLE SUBSTITUÉS ET LEURS UTILISATIONS
  申请人：ARQULE INC

  公开号：WO2009049305A2

  公开（公告）日：2009-04-16

  The present invention provides tetrazole compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the tetrazole compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention, formula (I) wherein: R1 is selected from the group consisting of hydrogen, CH3, F, Cl, Br, and I; R2 is selected from the group consisting of hydrogen, OH, SH, CH3, -CONH2, NHR16, -CH2OH, - CH2SH, and -CH2NH2; R16 is hydrogen, CH3, or C2H3; R3 is selected from the group consisting of hydrogen, F, Cl, Br, I, NO2, CN, -(C1-C6) alkyl, -(C1 -C6) substituted alkyl, C2-C6 alkenyl, (C3-C9) cycloalkyl, (C3-C9) substituted cycloalkyl; -OR8, -NR9R10, -C(=O)-, WR11, -C(=O)-NR12R13, and formula (II); R4 is selected from the group consisting of hydrogen, (C1 -C6) alkyl, (C1-C6) substituted alkyl, (C3-C9) cycloalkyl, (C3-C9) substituted cycloalkyl; aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyciyl, -OR14, and formula (III). The present invention relates to tetrazole compounds and the use of as HSP90 inhibitors for cancer.